What the Product Label Does Not Tell You About Drug-Drug Interaction Management: Time for a Re-Appraisal.

Burger, David M; le Comte, Marianne; Smolders, Elise J; Jacobs, Tom G; Ter Heine, Rob; Knibbe, Catherijne A J; Pirmohamed, Munir

Burger, David M; le Comte, Marianne; Smolders, Elise J; Jacobs, Tom G; Ter Heine, Rob; Knibbe, Catherijne A J; Pirmohamed, Munir.

Afiliação

Burger DM; Department of Pharmacy, Radboudumc Research Institute for Medical Innovation (RIMI), Radboudumc, The Netherlands.
le Comte M; Global DDI Solutions, Utrecht, The Netherlands.
Smolders EJ; Drug Information Center, Royal Dutch Pharmacists Association (KNMP), The Hague, The Netherlands.
Jacobs TG; Department of Pharmacy, Radboudumc Research Institute for Medical Innovation (RIMI), Radboudumc, The Netherlands.
Ter Heine R; Department of Clinical Pharmacy, Isala Hospital, Zwolle, The Netherlands.
Knibbe CAJ; Department of Pharmacy, Radboudumc Research Institute for Medical Innovation (RIMI), Radboudumc, The Netherlands.
Pirmohamed M; Department of Pharmacy, Radboudumc Research Institute for Medical Innovation (RIMI), Radboudumc, The Netherlands.

J Clin Pharmacol ; 63(11): 1181-1185, 2023 Nov.

Article em En | MEDLINE | ID: mdl-37477172

Palavras-chave

CYP3A; drug-drug interactions; product information; regulatory approval

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Clin Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google